Danish Medicines Council delays review of Leo Pharma's eczema treatment
Assessment of Leo Pharma’s tralokinumab is still dragging out at the Danish Medicines Council, which for a year has been unable to put together an expert committee due to the council’s impartiality policy. Leo Pharma calls for more transparency regarding the council’s challenges in that regard.
by ulrich quistgaard, translated by kristoffer grønbæk
The unclarified situation regarding Leo Pharma’s launch plans in Denmark for the company’s major growth hope, eczema treatment Adtralza (tralokinumab), continues after the Danish Medicines Council’s assessment on the medical treatment has been delayed.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
